Zoetis Toekomstige groei

Future criteriumcontroles 2/6

Zoetis zal naar verwachting groeien in winst en omzet met respectievelijk 9.9% en 5.8% per jaar. De winst per aandeel zal naar verwachting groeien met 10.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 45.9% zijn.

Belangrijke informatie

9.9%

Groei van de winst

10.6%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	23.8%
Inkomstengroei	5.8%
Toekomstig rendement op eigen vermogen	45.9%
Dekking van analisten	Good
Laatst bijgewerkt	06 Nov 2024

Recente toekomstige groei-updates

The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 04

Recent updates

The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 04

Zoetis: Long-Term Buy Despite Safety Concerns

May 03

Despite Lawsuit Risks: Why Zoetis Remains A Compelling Investment

Apr 15

Zoetis Inc.'s (NYSE:ZTS) Shareholders Might Be Looking For Exit

Apr 12

Zoetis: My Favorite Healthcare Stock Right Now

Mar 21

Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)

Mar 03

Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness

Feb 27

Animal Kingdom's Ally: Zoetis And Its Path To 10%+ Returns

Jan 10

Some Confidence Is Lacking In Zoetis Inc.'s (NYSE:ZTS) P/E

Jan 01

Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's

Dec 14

Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?

Dec 06

Here's Why We Think Zoetis (NYSE:ZTS) Might Deserve Your Attention Today

Nov 18

Zoetis: High-Quality Compounder With A Reasonable Price After Earnings

Nov 09

Zoetis: Significant CapEx Investments For Long-Term Growth, But A Hold Now

Oct 26

Zoetis Is An Impressive Healthcare Compounder

Sep 26

Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Sep 25

Here's Why Zoetis (NYSE:ZTS) Can Manage Its Debt Responsibly

Sep 04

Zoetis: Pawses Pain, Librela OA Treatment Targets Furry Friends In The U.S.

Aug 22

Should You Be Adding Zoetis (NYSE:ZTS) To Your Watchlist Today?

Aug 12

Zoetis: My Dog Approves Of This Dividend Compounder

Jul 19

Zoetis: A Purrfect Addition To Your Portfolio

Jun 22

Does This Valuation Of Zoetis Inc. (NYSE:ZTS) Imply Investors Are Overpaying?

Jun 10

These 4 Measures Indicate That Zoetis (NYSE:ZTS) Is Using Debt Reasonably Well

Apr 16

Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Mar 10

Zoetis rises on 2023 revenue forecast above estimates, Q4 profit in-line with consensus

Feb 14

Winst- en omzetgroeiprognoses

NYSE:ZTS - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	10,384	3,034	2,957	3,420	14
12/31/2025	9,725	2,719	2,630	3,165	15
12/31/2024	9,262	2,461	2,219	2,712	11
9/30/2024	9,152	2,430	2,308	2,945	N/A
6/30/2024	8,915	2,344	2,103	2,718	N/A
3/31/2024	8,734	2,391	1,750	2,399	N/A
12/31/2023	8,544	2,344	1,621	2,353	N/A
9/30/2023	8,371	2,280	1,492	2,197	N/A
6/30/2023	8,222	2,213	1,285	1,999	N/A
3/31/2023	8,094	2,071	1,458	2,152	N/A
12/31/2022	8,080	2,114	1,326	1,912	N/A
9/30/2022	8,007	2,067	1,267	1,850	N/A
6/30/2022	7,995	2,090	1,429	1,977	N/A
3/31/2022	7,891	2,073	1,607	2,122	N/A
12/31/2021	7,776	2,037	1,736	2,213	N/A
9/30/2021	7,616	1,982	1,791	2,252	N/A
6/30/2021	7,412	1,909	1,702	2,161	N/A
3/31/2021	7,012	1,774	1,682	2,118	N/A
12/31/2020	6,675	1,638	1,673	2,126	N/A
9/30/2020	6,542	1,663	1,523	1,990	N/A
6/30/2020	6,340	1,617	1,456	1,934	N/A
3/31/2020	6,339	1,611	1,323	1,814	N/A
12/31/2019	6,260	1,500	1,335	1,795	N/A
9/30/2019	6,150	1,461	1,365	1,797	N/A
6/30/2019	6,046	1,375	1,463	1,841	N/A
3/31/2019	5,914	1,388	1,442	1,790	N/A
12/31/2018	5,825	1,428	1,452	1,790	N/A
9/30/2018	5,721	1,164	1,531	1,814	N/A
6/30/2018	5,588	1,115	N/A	1,703	N/A
3/31/2018	5,442	978	N/A	1,616	N/A
12/31/2017	5,307	864	N/A	1,346	N/A
10/1/2017	5,124	937	N/A	1,024	N/A
7/2/2017	5,018	878	N/A	824	N/A
4/2/2017	4,957	855	N/A	781	N/A
12/31/2016	4,888	821	N/A	713	N/A
10/2/2016	4,885	689	N/A	705	N/A
7/3/2016	4,858	639	N/A	670	N/A
4/3/2016	4,825	378	N/A	655	N/A
12/31/2015	4,765	339	N/A	664	N/A
9/27/2015	4,811	443	N/A	773	N/A
6/28/2015	4,807	420	N/A	672	N/A
3/29/2015	4,790	593	N/A	709	N/A
12/31/2014	4,785	583	N/A	626	N/A
9/28/2014	4,719	562	N/A	537	N/A
6/29/2014	4,612	527	N/A	548	N/A
3/30/2014	4,568	519	N/A	377	N/A
12/31/2013	4,561	504	N/A	681	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei ZTS ( 9.9% per jaar) ligt boven de spaarquote ( 2.6% ).

Winst versus markt: De winst van ZTS ( 9.9% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 15.6% per jaar).

Hoge groeiwinsten: De winst van ZTS zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van ZTS ( 5.8% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van ZTS ( 5.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen ZTS zal naar verwachting over 3 jaar zeer hoog zijn ( 45.9 %).

Zoetis Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Zoetis Inc. Raises Revenue Guidance for the Full Year 2024

Zoetis Inc. Raises Earnings Guidance for the Year 2024

The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Zoetis Inc. Revises Earnings Guidance for the Year 2024

Zoetis Inc. Provides Earnings Guidance for the Full Year 2023

Zoetis Inc. Maintains Earnings Guidance for the Full Year 2023

Recent updates

Zoetis Inc. Announces Executive Changes

Zoetis Inc. Raises Revenue Guidance for the Full Year 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Zoetis (NYSE:ZTS) Has A Pretty Healthy Balance Sheet

Second quarter dividend of US$0.43 announced

Zoetis Inc. Declares Fourth Quarter 2024 Dividend, Payable on December 3, 2024

Zoetis: A Solid Choice For The Young Dividend Growth Investor

Do Zoetis' (NYSE:ZTS) Earnings Warrant Your Attention?

Zoetis: Investing In Pet Health And Portfolio Wealth

Are Investors Undervaluing Zoetis Inc. (NYSE:ZTS) By 23%?

Zoetis to Introduce First Cartridge-Based AI-Powered Hematology Analyzer

There's Reason For Concern Over Zoetis Inc.'s (NYSE:ZTS) Price

Now 22% undervalued

Zoetis: Librela Sales Should Peak 200-300% Above Management's $1B Target

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Zoetis Q2 Earnings: Harvesting From DTC (Rating Upgrade)

Zoetis Inc. Raises Earnings Guidance for the Year 2024

Zoetis Inc. (NYSE:ZTS) announces an Equity Buyback for $6,000 million worth of its shares.

Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?

Upcoming dividend of US$0.43 per share

Executive VP & CFO exercised options and sold US$2.4m worth of stock

Zoetis: A High-Quality Business And Fast Dividend Growth At A Reasonable Price

Zoetis: Don't Fret Excessively Over The Animal Healthcare Leader

A Look At The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

First quarter dividend of US$0.43 announced

Zoetis Inc. Announces Retirement of Linda Rhodes as Board of Directors

Zoetis (NYSE:ZTS) Ticks All The Boxes When It Comes To Earnings Growth

Zoetis Inc. Declares Dividend for the Third Quarter of 2024, Payable on September 4, 2024

Zoetis: Why The Focus On Companion Animal Segment Will Pay Off

Employee Advisor notifies of intention to sell stock

The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Zoetis: Long-Term Buy Despite Safety Concerns

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Zoetis Inc. Revises Earnings Guidance for the Year 2024

Phibro Animal Health Corporation (NasdaqGM:PAHC) entered into a definitive agreement to acquire Medicated feed additive product portfolio, certain water soluble products and related assets of Zoetis Inc. (NYSE:ZTS) for approximately $350 million.

Zoetis Inc. Announces Executive Changes

Despite Lawsuit Risks: Why Zoetis Remains A Compelling Investment

Now 22% undervalued after recent price drop

Zoetis Inc.'s (NYSE:ZTS) Shareholders Might Be Looking For Exit

Zoetis Inc., Annual General Meeting, May 22, 2024

Upcoming dividend of US$0.43 per share

Zoetis Inc. Appoints Gavin D.K. Hattersley to Its Board of Directors

Zoetis: My Favorite Healthcare Stock Right Now

Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)

Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness

CEO & Director notifies of intention to sell stock

CEO & Director exercised options and sold US$3.6m worth of stock

Full year 2023 earnings: EPS misses analyst expectations

Dividend of US$0.43 announced

Zoetis Inc. Declares Second Quarter 2024 Dividend, Payable on June 4, 2024

Upcoming dividend of US$0.43 per share at 0.9% yield

Animal Kingdom's Ally: Zoetis And Its Path To 10%+ Returns

Some Confidence Is Lacking In Zoetis Inc.'s (NYSE:ZTS) P/E

Insufficient new directors

Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's

Zoetis Inc. Declares Dividend for the First Quarter of 2024, Payable on March 1, 2024

Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?

CEO & Director exercised options and sold US$1.7m worth of stock

Here's Why We Think Zoetis (NYSE:ZTS) Might Deserve Your Attention Today

Zoetis: High-Quality Compounder With A Reasonable Price After Earnings

Zoetis Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Zoetis: Significant CapEx Investments For Long-Term Growth, But A Hold Now

Upcoming dividend of US$0.38 per share at 0.9% yield

Zoetis Inc. Declares Dividend for the Fourth Quarter of 2023, Payable on December 1, 2023

Zoetis Is An Impressive Healthcare Compounder

Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Executive VP notifies of intention to sell stock

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH from founders, High-Tech Gründerfonds, the Swiss Occident Group AG and MorphoSys AG (XTRA:MOR).